The Philippine Council for Health Research and Development (PCHRD) and the De La Salle Health Sciences Institute (DLSHSI) signed a Memorandum of Agreement (MOA) on 10 May 2018 at DLSHSI, Cavite for a community approach study to control and halt Drug Resistant TB (COACH - DRTB).

PCHRD and DLSHSI have long been partners in research to help improve the current TB problem in the country. Executive Director Dr. Jaime Montoya and Division Chief Ms. Merle Opeña represented PCHRD while DLSHSI was represented by University President Br. Augustine L. Boquer during the ceremonial signing.

COACH –DRTB is a five-year long project that will support the National TB Program in formulating the policies and guidelines in investigating household contacts of active TB cases as well as in formulating the guidelines in enhancing the support of local partners in managing TB in their community.

Dr. Charles Yu, Vice Chancellor for Research Division at DLSHSI and proponent of the study, said that the research will determine the effectiveness of COACH – DRTB strategy in the detection and treatment of DRTB. Expected outputs of the project are to formulate policies and guidelines to enhance and develop the support of community partners in managing TB at their locale, train and mentor community health workers as TB treatment partners, and foster collaboration among government institutions, LGUs, and community health offices. Results of standardized data and specimen collection of the study will also be sent to Regional Prospective Observational Research in Tuberculosis (RePORT) International as bases for future collaborative efforts on TB.

One of the highlights of the MOA signing was when both Dr. Montoya and Br. Boquer gave meaningful statement to solidify the collaboration. According to Dr. Montoya, this project is one of the biggest projects to be funded by the Council which means that TB remains as a priority disease that has to be the focus of the Council’s attention and resources. He added that the Council has full confidence and trust that DLSHSI as an institution can conduct the research that will hopefully have a significant contribution to the national effort to control TB in the Philippines.

While Br. Boquer expresses gratitude to the Council for giving DLSHSI the opportunity to help other people and to improve delivery of health care through scientific research. He assured that DLSHSI is committed in seeing the project through and delivering results.

In addition, Dr. Montoya reminded everyone that “as a national coordinating agency for health research, your success is our [PCHRD] success and that we all work for a common goal and that is to provide the best quality healthcare for each and every Filipino.”


The Philippine Council for Health Research and Development held a forum on the TB Filipino Impact Testing (FIT): Impact Assessment of Diagnostic Algorithms and Tools for Multi-Drug Resistant (MDR-TB) and Drug Sensitive Tuberculosis (TB) in the Philippines last April 25, 2018 at the NIH Conference Room, UP Manila.

Proponent of the study Dr. Charles Yu of De La Salle Health Sciences Institute (DLSHSI) and Mr. Ewan Tomeny from the Liverpool School of Tropical Medicine (LSTM) in UK delivered the presentation on the initial results and future implications of the project on the cost effectiveness of TB diagnosis in the country.

TB FIT is one of the projects under the Newton Agham program under the Medical Research Council (MRC) – UK and PCHRD collaboration. The program extends assistance to projects that helps improve health outcomes through research-based solutions and innovations.

According to Dr. Yu, the study is being conducted to support the cost-effective roll-out of new tools and algorithms for the diagnosis of multi-drug resistant tuberculosis and drug-sensitive tuberculosis in the Philippines. He explained that this will lead to the delivery of improvement to TB/MDR-TB case detection in the Philippines, as well as promote the economic development and welfare of the country.

The project developed a computer model to assess the impacts of different diagnostic algorithms for TB including new and currently available tools. It was designed to represent patient pathways at specific sites that will be used to compare the impacts and cost-effectiveness of different diagnostic algorithms.

Initial results from modelling Cavite sites shows that rolling out GeneXpert as a replacement to microscopy is cost-effective where drug sensitive and MDR-TB cases are correctly treated. Moreover, it has been shown that most of the alternative diagnostic algorithms modelled would significantly reduce patient costs .

Mr. Ewan Tomeny discussed that  the virtual implementation modelling can provide a better understanding of current and potential future patient pathways through visualization, comparison of options by projecting the patient and health systems evidence over extended timeframes, estimation of patient and health system costs, and assessment of incremental cost effectiveness of scale up.

The next stage of the research will look at data from additional provinces in the Philippines. Data will shortly be available for Davao and Bulacan. LSTM will support the DLSHSI and National TB Control Program (NTP) in using the models to evaluate alternative diagnostic algorithms in these provinces and then across the Philippines.

The forum was an opportune moment for researchers and medical practitioners to discuss and assess the current TB situation in the Philippines, most of them were interested in using the model and apply it to the detection of other diseases such as dengue or HIV.

TB FIT is one of the six projects of the 1st cycle of the Newton Agham program that is able to produce quality results that impacts public health. Encouraged by the success of the first six projects in Cycle 1, the Medical Research Council – UK (MRC) and PCHRD launched the second cycle of the Newton Fund last March 2, 2017 where 12 concept proposals were shortlisted for full proposal development.

Philippine Council for Health Research and Development (PCHRD) Executive Director, Dr. Jaime C. Montoya led the presentation of the accomplishments in health research and development at the 3rd National Research and Development Conference (NRDC) last 20 April 2018 at the Philippine International Convention Center (PICC).

Scientists and researchers of the country came together at the annual conference to present projects on five sector components: (1) basic research, (2) agriculture, aquatic, and natural resources, (3) health, (4) industry, energy, and emerging technology, and (5) disaster risk reduction and climate change adaptation.

Underlining the Council’s support in every stage in health research, Dr. Montoya discussed the Council’s accomplishments of the previous year and the exciting developments to look forward to this 2018.

The health sector had a notable lineup of four speakers starting with Dr. Mario V. Capanzana of the Food and Nutrition Research Institute who talked about the Malnutrition Reduction Program.

Dr. Raul V. Destura of UP Manila and the Philippine Genome Center presented the “Lab-in-a-Mug Project: How Dengue brought us together,” and highlighted the development and the process behind the affordable, accurate, and rapid test kit for accurate detection of dengue infection—Biotek-MTM Dengue aqua kit. Biotek-MTM recently received a gold medal at the Salon International des Inventions de Genève.

The “Axis Knee System: Confidence in Every Step” by Dr. Ilustre I. Guloy of the Orthopaedic International Inc. and Asian Hospital and Medical Center discussed the cost-efficient, simple, and revolutionary knee replacement system that is now commercially available for individuals suffering from severe osteoarthritis.

Dr. Evangeline C. Amor discussed one of the projects under the Tuklas Lunas Program: Discovery and Development of Health Products: Terrestrial Herbals and Drug Candidates, a collaborative research program among institutions across the country. Supplements and medicine for disease such as diabetes, inflammation and pain, hypertension and high cholesterol, gout, and microbial infection could be made available through the discoveries of the projects.

DOST Secretary Fortunato T. de la Peña also recognized the recipients of the first Niche Centers in the Regions for R&D (NICER) Program and Collaborative Research and Development to Leverage Philippine Economy (CRADLE) Program.

Among the grantees are the health researches monitored by the Council, namely: Center for Innovations for Cost Effective Disaster Risk Reduction and Management in Health (DRRM-H) outcomes in NCR and the Philippines by Dr. Carlos Primero Gundran of University of the Philippines Manila (NICER); PCOPEIA: Predictive Chromatography of Organic Plant Extracts with Intelligent Agents by Dr. Dranreb Earl Juanico of Technological Institute of the Philippines and Dr. Isagani Padolina of Pascual Pharma Corp (CRADLE); and M of Hypocholesterolemic Natural Products from Pineapple by Dr. Jonel Saludes of University of San Agustin.

The conference showcased updates on the Harmonized National R&D Agenda (HRNDA 2017-2022). The NRDC is an annual gathering to consult and gather inputs of government agencies, private R&D institutions, the academe, industry, and other concerned agencies for research and development plans and programs.



Hemophilia is a bleeding disorder, passed on from mothers, which affects the blood’s ability to clot. The World Hemophilia Federation estimates that about 10,000 Filipinos have hemophilia, with about 1 million suffering from Von Willebrand disease and other bleeding disorders. As we celebrate the Hemophilia Awareness Month this April, here are five facts on hemophilia gathered from a study entitled "Hemorrhagic diseases in Filipino children” published in The Philippine Journal of Pediatrics.

  1. There are two common types of hemophilia

Hemophilia A is the most common type of hemophilia that occurs in about 1 in 5000 males caused by missing or defective factor VIII. Hemophilia B is a less common type of hemophilia that occurs in about 1 in 25000 male births caused by missing or defective factor IX. Having a defective factor means that the body of person has no means to repair itself when there is damage in the blood vessel or injured tissue that will lead to excessive bleeding and internal hemorrhaging.

  1. Uncontrolled bleeding occurs

A more serious concern for people suffering from hemophilia is spontaneous bleeding; any leak can cause severe bleeding and the body will not heal itself. Bleeding into different organs can be life threatening because when it occurs to a vital organ, it can cause permanent damage beyond repair.

  1. It affects children

Hemophilia B Leyden is an extremely rare form of Hemophilia B that causes young children to bleed excessively throughout childhood but when they reach puberty, very little bleeding occurs afterward.

  1. Women can get affected too

Hemophilia is a recessive x-linked trait which affects approximately 1 in 4500 males, but there are cases in which the mutation can cause the same disease issue to the carrier [mothers].

  1. No cure available yet

Medical scientists haven’t found a cure yet for this condition. The only treatment available for hemophilia is replacement therapy wherein, concentrates of clotting factor VIII (for hemophilia A) and IX (for hemophilia B) are slowly dripped or injected into a vein. This helps in replacing the defective clotting factor of the blood. Out of the 10000 Filipinos that suffer from hemophilia, 3 out of every 4 people lack the resources required for proper treatments.

This research is one of the many studies on hemophilia uploaded in the Health Research and Development Information Network (HERDIN), an online database of PCHRD that enables online publishing, exchanging, and dissemination of quality health information in the Philippines. It is the only health research repository for published researches in the county.

In the spirit of raising awareness on Hemophilia Month, PCHRD invites universities, colleges, laboratories, and medical and research institutions to upload their published and unpublished researches to HERDIN to expand the reach of their study and foster collaboration to find research-based solutions to healthcare problems such as hemophilia.

For more information, you can visit HERDIN’s website at http://www.herdin.ph/

 

BIOTEK-MTM Dengue Aqua Kit , a Department of Science and Technology – Philippine Council for Health Research and Development (DOST-PCHRD) assisted technology, was one of the gold awardees during the 46th International Exhibition of Inventions Geneva held on 11-15 April 2018 at Palexpo, Geneva.

Engr. Edgar Garcia, Director of Technology Application and Promotion Institute (DOST-TAPI), and Ambassador Evan Garcia, Representative of the Philippines to UN and Other International Organizations in Geneva, accepted the award for the Filipino Inventions and DOST-assisted technologies - Smart Surface and BIOTEK-M during the event.

BIOTEK-M is an affordable and locally developed rapid test kit for accurate detection of dengue infection within an hour. It is part of the “Lab-in-a-Mug Project” where diagnostic kits are integrated in an isothermal unit as small as a “mug” which functions as a diagnostic device similar to a portable laboratory. The local innovation has high sensitivity, high specificity, robust, and is less expensive than current diagnostic tests in the market.

It was created by experts from the Institute of Molecular Biology and Biotechnology, National Institutes of Health, University of the Philippines Manila led by Dr. Raul Destura. BIOTEK-M was developed through funding from DOST, PCHRD, and its commercialization is supported by TAPI.

The development of the technology generated the first spin-off company from the University of the Philippines since 1908, the Manila Healthtek, Inc. The R&D company on health biotechnology focuses on developing and providing affordable diagnostic technologies for communicable and non-communicable diseases.

BIOTEK-M was one of the thousand inventions on display during the international exhibition. Inventions related to health, medicine, environment and safety had the strongest presence during the show. In fact, the Grand Prix is a medical invention from Hong Kong, a multi-segment lens for glasses designed to defocus short-sighted vision which enables myopia to be controlled.

The exhibition is regarded as the world's most important event exclusively dedicated to inventions and a unique marketplace for industry professionals. This year, the annual exhibition attracted 31,050 visitors, 822 exhibitors, and 1000 innovations from more than 40 countries.